CuraVac is a clinical-stage biotech company developing Therapeutic Vaccines and Active Targeted Immunotherapies for autoimmune diseases. With the use of a new revolutionary technique based on complementary peptides, we aim to induce long-term immunity against autoimmune diseases such as Multiple Sclerosis (MS), Myasthenia Gravis (MG), diabetes, Graves’ disease, Systemic Lupus Erythematosus (SLE) and Hashimoto’s disease.
CuraVac’s lead candidate therapeutic vaccine for myasthenia gravis, CV-MG, has already completed the clinical study phase 1B with an excellent safety profile and we are curently preparing a phase 2 efficacy demonstration clinical trial.
CuraVac’s CV-MG is a potential breakthrough in MG treatments and a potential therapeutic revolution for all autoimmune diseases – being the first to possibly bring a long-lasting improvement and a potential cure to patients.
CuraVac is a clinical-stage biotech company developing the medical and commercial potential of a revolutionary technique for the production of specific therapeutic vaccines for the treatment of autoimmune diseases.
The CuraVac team is composed of 3 key people at the center of a collaborative network of the highest quality from the industry and the academic world: Dr. Stéphane Huberty, Professor J. Edwin Blalock and Nicolas Havelange.
CuraVac’s Independent Advisory Board is composed of key specialists from the industry and the academic world who provide the management team with valuable input in its strategic decision making.
MYASTERIX started as a 5-year collaborative research project in October 2013. It was coordinated by CuraVac and supported by the European Commission.
CuraVac was founded in 2002 by Dr. Stéphane Huberty, a Belgian medical doctor who suffered from Myasthenia Gravis. Soon after, the company acquired the complementary peptide patent, raised funds and got organized as a management company at the center of a network of collaborations and sub-contracting companies. The original discoverer of the vaccine production technique, Professor J. Edwin Blalock also joined CuraVac as a consultant.
“They didn’t know it was impossible so they did it” (Mark Twain)